[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640970":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":7,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":7,"enrollmentInfo":29,"targetDuration":32,"studyType":33,"phases":7,"briefSummary":34,"conditions":35,"keywords":7,"overallStatus":37,"whyStopped":7,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"Ipsen","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Ipsen Medical Director","STUDY_DIRECTOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Ipsen Clinical Study Enquiries","CONTACT","See e mail","clinical.trials@ipsen.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100640970","a-study-to-observe-the-long-term-safety-of-odevixibat-in-patients-with-alagille-syndrome-algs-who-are-receiving-ongoing-treatment-100640970",false,"NCT07585097","A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment","Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)","Inclusion Criteria:\n\n* Diagnosed with ALGS.\n* On (or starting) active odevixibat treatment.\n* Aged 6 months or older at the time of consent.\n\nExclusion Criteria:\n\n* Currently participating in a clinical trial with odevixibat.\n* Currently participating in any interventional clinical trial for ALGS.\n* Have any contraindication to odevixibat as per the locally approved label.","ALL","6 Months",{"count":30,"type":31},30,"ESTIMATED","2 Years","OBSERVATIONAL","This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.\n\nThe main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.",[36],"Alagille Syndrome","NOT_YET_RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":31},"2026-09-30",{"date":45,"type":31},"2031-09-30",{"name":5,"class":6}]